Trevejo Jose M.'s Form 4 filing
Tarsus Pharmaceuticals, Inc. (TARS) · filed Mar 23, 2023
- Accession no.
- 0001661539-23-000004
- Filed
- Mar 23, 2023
- Trade date
- Mar 21-23, 2023
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 3 non-derivative transactions. Open-market sales total $19.0K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Trevejo Jose M.CIK 0001661539 | Officer (CHIEF MEDICAL OFFICER) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 21, 2023 | Common Stock | SSaleDisposed | −519 | $12.89 | −$6,689.91 | 7,101 | Direct | |
| Mar 22, 2023 | Common Stock | SSaleDisposed | −529 | $12.64 | −$6,686.56 | 6,572 | Direct | |
| Mar 23, 2023 | Common Stock | SSaleDisposed | −465 | $12.15 | −$5,649.75 | 6,107 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.